header

NanoTech and Immunoengineering: How Nanotech Can Boost CAR-T Therapy

56 Pages Posted: 10 Jan 2020 First Look: Accepted

See all articles by Waqas Nawaz

Waqas Nawaz

Nanjing University - Center for Public Health Research

Shijie Xu

Nanjing University - Center for Public Health Research

Yanlei Li

Y-Clone Medical Science Co. Ltd

Bilian Huang

Nanjing University - Center for Public Health Research

Xilin Wu, PhD

Nanjing University - Center for Public Health Research

Zhiwei Wu

Nanjing University - Center for Public Health Research

Abstract

Chimeric antigen receptor (CAR) therapy has achieved remarkable clinical efficacy against hematological cancers and got FDA approval for B cells tumor. However, the complex manufacturing process and limited success in solids tumors hamper its widespread applications and provoke new strategies to overcome above-mentioned hurdles. In last decade, nanotech provides sustainable strategies to improve cancer immunotherapy for vaccine development, and in delivery of immunomodulatory drugs. Nanotech can boost the CAR-T therapy and may overcome the existing challenges by emerging as a carrier for CAR therapy, or in a joint venture it may defeat the solid tumor more effectively than the conventional approaches. However, the unraveling of cellular mechanisms, barriers, and the potential strategies that could be used to manipulate and/or educate cells would enable unprecedented advances in nanotech for biologics delivery. This review outlines the journey and barriers of nanoparticles (NPs) across the cell. Afterward, the approaches to tackle those barriers and strategies to modulate NPs as a carrier for CAR therapy are discussed. Finally, the role of NPs in CAR-T therapy and the potential challenges are summarized. The main purpose of this review is to provide the readers with a detailed overview of NPs based CAR-T therapy research, and distill this information into an accessible form conducive to design desired CAR therapy by NPs approach.

Keywords: Chimeric antigen receptor, Nanocarriers, intracellular transport, Immunoengineering, Nano-immunotherapeutics, tumor microenvironment, Immune cells

Suggested Citation

Nawaz, Waqas and Xu, Shijie and Li, Yanlei and Huang, Bilian and PhD, Xilin Wu, and Wu, Zhiwei, NanoTech and Immunoengineering: How Nanotech Can Boost CAR-T Therapy. Available at SSRN: https://ssrn.com/abstract=3509332 or http://dx.doi.org/10.2139/ssrn.3509332

Waqas Nawaz

Nanjing University - Center for Public Health Research

Nanjing
China

Shijie Xu

Nanjing University - Center for Public Health Research

Nanjing
China

Yanlei Li

Y-Clone Medical Science Co. Ltd

Suzhou
China

Bilian Huang

Nanjing University - Center for Public Health Research

Nanjing
China

Xilin Wu, PhD

Nanjing University - Center for Public Health Research

Nanjing
China

Zhiwei Wu (Contact Author)

Nanjing University - Center for Public Health Research ( email )

Nanjing
China

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
186
Downloads
33